AiCure

Articles Published in 2014

BioMarin to acquire Prosensa for $680M

Tuesday, November 25, 2014 08:30 AM

BioMarin Pharmaceutical, based in San Rafael, Calif., will acquire Prosensa for $17.75 per share, for a total up-front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016, and Europe no later than Feb. 15, 2017, respectively.

More... »


CytRx announces partial clinical hold affecting aldoxorubicin clinical trials

Monday, November 24, 2014 02:58 PM

CytRx, a biopharmaceutical R&D company specializing in oncology, has received notice from the FDA that its clinical trials for aldoxorubicin have been placed on partial clinical hold. All currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols, but no new patients can be enrolled until the clinical hold is lifted.

More... »


Report: 80% of pharma outsource some of their government reimbursement budgets

Monday, November 24, 2014 02:53 PM

Eighty percent of surveyed pharma companies outsource some portion of their government reimbursement budgets, including third-party audits that can help companies remain compliant to changing industry guidelines, according to Cutting Edge Information, a Research Triangle Park, N.C.-based pharmaceutical business intelligence provider.

More... »

Cell Therapy Catapult, partners launch U.K. database of research funding

Monday, November 24, 2014 02:50 PM

The Cell Therapy Catapult, focused on the development of the U.K. cell therapy industry, has collaborated with the U.K. Regenerative Medicine Platform, the Knowledge Transfer Network and the Association of Medical Research Charities to develop a database of U.K. cell therapy research funding.

More... »

SEC suspends trading in companies touting Ebola-related prevention/treatment operations

Monday, November 24, 2014 02:49 PM

The Securities and Exchange Commission has suspended trading in four companies that claim to be developing products or services in response to the Ebola outbreak, citing a lack of publicly available information about the companies' operations.

More... »

Gates Foundation to support Ebola-affected countries, accelerate treatment evaluation

Monday, November 24, 2014 02:46 PM

The Bill & Melinda Gates Foundation, based in Seattle, Wash., will be supporting efforts in Guinea and other Ebola-affected countries to scale up the production and evaluation of convalescent plasma and other convalescent blood products as potential therapies for people infected with the Ebola virus. Various drug candidates also will be evaluated, including the experimental antiviral drug brincidofovir.

More... »

Almac, ESMS Global collaborate

Monday, November 24, 2014 02:45 PM

Almac, a global provider of advanced clinical technology and support services, and ESMS, a 24/7 medical emergency response service for clinical trials based in the U.K., are collaborating to offer clients an exclusive solution surrounding emergency unblinding procedures.

More... »

AstraZeneca to expand its Maryland biologics manufacturing center, add 300 jobs

Monday, November 24, 2014 02:44 PM

AstraZeneca plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility to support AZ’s maturing pipeline, and will help the company keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AZ’s overall pipeline.

More... »

NextDocs joins the Parexel Perceptive Partner Program

Monday, November 24, 2014 02:41 PM

NextDocs, a Conshohocken, Pa.-based provider of regulated content management and compliance solutions for the life sciences industry, has joined the Parexel Perceptive Partner Program. NextDocs will enhance and broaden its services to biopharmaceutical customers by leveraging the Perceptive MyTrials eClinical platform, a suite of applications for managing clinical trials. 

More... »

Innovate U.K., Medical Research Council award $47.1M

Monday, November 24, 2014 02:37 PM

Innovate U.K. and the Medical Research Council have awarded over $47.1 million in new funding through the Biomedical Catalyst, part of the U.K. government’s life sciences strategy.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs